clinical trial · NCT07553442
A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran
HypertensionALN-AGT01 RVRPlaceboZilebesiran
brief summary
The purpose of this study is to evaluate the efficacy, pharmacodynamics (PD), and safety of ALN-AGT01 RVR in participants with mild to moderate hypertension pretreated with zilebesiran.
started
Apr 27, 2026
primary completion
Apr 1, 2028
completion
Oct 1, 2028
last updated
May 14, 2026
detailed description
This study will be conducted in 2 parts:
* Part A: Single dose (SD), dose-ranging part in adults with mild to moderate hypertension. * Part B: SD in adults with mild to moderate hypertension.
official title
A Phase 2, Randomized, Double-blind, Placebo-controlled, Single Dose Study of the Efficacy, Pharmacodynamics, and Safety of ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol